Nabriva Therapeutics AG (Nasdaq: NBRV) to Ring The Nasdaq Stock Market Closing Bell
Get Alerts NBRV Hot Sheet
Join SI Premium – FREE
ADVISORY, May 31, 2016 (GLOBE NEWSWIRE) --
What:Nabriva Therapeutics AG (Nasdaq: NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Dr. Colin Broom, Chief Executive Officer, will ring the Closing Bell.
Where:Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:Wednesday, June 1, 2016 – 3:45 p.m. to 4:00 p.m. ET
Nabriva Therapeutics AG Media Contact:Will SargentNabriva Therapeutics AG[email protected]
Nasdaq MarketSite:Emily Pan(646) 441-5120[email protected]
Feed Information:Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our Tumblr page:http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of the Market Close, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market close of your choice.
About Nabriva Therapeutics AGNabriva Therapeutics is a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva's medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate. Nabriva's lead pleuromutilin product candidate, lefamulin, is being developed to be the first systemically available pleuromutilin for human use and is the first new class of antibiotic to reach late stage clinical development for CABP in over a decade. Nabriva believes lefamulin is well positioned for use as a first-line empiric monotherapy for the treatment of moderate to severe CABP due to its novel mechanism of action, targeted spectrum of activity, resistance profile, achievement of substantial drug concentration in lung tissue and fluid, oral and IV formulations and favorable tolerability profile. Nabriva also intends to further pursue the development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections, and is developing a formulation of lefamulin appropriate for pediatric use.
Nabriva owns exclusive, worldwide rights to lefamulin, which is protected by composition of matter patents issued in the United States, Europe and Japan.
About NasdaqNasdaq (Nasdaq: NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.3 trillion and nearly 17,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.
-NDAQA-
Source: NASDAQ, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple (AAPL) announces 'Let Loose,' a special online event to be held in May
- Run-Ops Brings A Pragmatic, Results-Focused Approach To The Business Consulting Landscape
- America's Deadly Roads Are Not Getting Safer
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!